Depletion of CD25 + CD4 + T cells (Tregs) enhances the HBV-specific CD8 + T cell response primed by DNA immunization

Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)C...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 11; no. 24; pp. 3772 - 3777
Main Author Furuichi, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan 28.06.2005
Baishideng Publishing Group Inc
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v11.i24.3772

Cover

Abstract Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization. B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining. DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells. CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.
AbstractList Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization. B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining. DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells. CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.
AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25+CD4+ regulatory T (Treg) cells might be involved in a inhibition of CD8+ T cell priming or in the modulation of the magnitude of the ‘peak’ antiviral CD8+ T cell response primed by DNA immunization. METHODS: B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 μg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25+ cells. Induction of HBV-specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-γ staining. RESULTS: DNA immunization induced HBV-specific CD8+ T cells. At the peak T cell response (d 10), 7.1±2.0% of CD8+ T cells were HBV-specific after DNA immunization, whereas 12.7±3.2% of CD8+ T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8+ T cells in the absence of CD25+ Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3±0.4%) in comparison to Treg-depleted mice (2.6±0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-γ production and the avidity of the HBV-specific CD8+ T cell response to antigen were higher in HBV-specific CD8+ T cells induced in the absence of Treg cells. CONCLUSION: CD25+ Treg cells suppress priming and/or expansion of antigen-specific CD8+ T cells during DNA immunization and the peak CD8+ T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8+ T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.
R5; AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25+CD4+ regulatory T (Treg) cells might be involved in a inhibition of CD8+T cell priming or in the modulation of the magnitude of the'peak' antiviral CD8+ T cell response primed by DNA immunization. METHODS: B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 μg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25+ cells. Induction of HBV-specific CD8+ T ceils in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-γ staining.RESULTS: DNA immunization induced HBV-specific CD8+ T cells. At the peak T cell response (d 10), 7.1±2.0% of CD8+ T cells were HBV-specific after DNA immunization, whereas 12.7±3.2% of CD8+ T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8+ T cells in the absence of CD25+ Treg cells (n = 6, P<0.05). Similarly, fewer HBVspecific memory T cells were detected in the presence of these cells (1.3±0.4%) in comparison to Treg-depleted mice (2.6±0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-γ production and the avidity of the HBV-specific CD8+ T cell response to antigen were higher in HBV-specific CD8+ T cells induced in the absence of Treg cells.CONCLUSION: CD25+ Treg cells suppress priming and/or expansion of antigen-specific CD8+ T cells during DNA immunization and the peak CD8+ T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8+ T ceil response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.
Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.AIMPersistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.METHODSB10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.RESULTSDNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.CONCLUSIONCD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.
Author Furuichi, Yoshihiro
AuthorAffiliation Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan
AuthorAffiliation_xml – name: Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan
Author_xml – sequence: 1
  givenname: Yoshihiro
  surname: Furuichi
  fullname: Furuichi, Yoshihiro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15968737$$D View this record in MEDLINE/PubMed
BookMark eNqFkc2P0zAQxS20iO0u3DkhHxACoRR_JY4vSEsLLNIKLoWr5TiT1lVqZ-Nkq_LX49CKBQ5wsSXPm5n3fr5AZz54QOgpJXMuRflmv13P7yidOybSg2QP0IwxqjJWCnKGZpQQmSnO5Dm6iHFLCOM8Z4_QOc1VUUouZ2hYQtfC4ILHocGLJcvx63SJdK6whbaN-OWqh3V8hcFvjLcQ8bABfP3uWxY7sK5xNunLX3rcQ-yCj4C73u2gxtUBLz9fYbfbjd59N9Oqx-hhY9oIT073Jfr64f1qcZ3dfPn4aXF1k1me8yEz0jaNMrSsi6aiVqiCKpNbkYoVr6kEqXJQthZ1DjxXQjJFZEkrXlaqKnnJLxE9zh19Zw5707Z6MmX6g6ZETwR1IqgTQZ0I6olg6nl77OnGKtm34Ife3PcF4_SfFe82eh3utOC0IJynAc-PA_bGN8av9TaMvU8xp12MkJwJwkSSvTjt6cPtCHHQOxcngMZDGKMuUriCcpqEz343dJ_g9IdJUBwFtg8x9tBo64afnJM_1_4rKvmr8b90fgArGb-D
CitedBy_id crossref_primary_10_1128_JVI_00036_09
crossref_primary_10_2217_imt_09_26
crossref_primary_10_3389_fimmu_2022_993246
crossref_primary_10_1016_j_bbrc_2008_04_191
crossref_primary_10_1016_j_imlet_2015_05_018
crossref_primary_10_1016_j_clim_2010_12_012
crossref_primary_10_1146_annurev_immunol_021908_132723
crossref_primary_10_1097_CJI_0000000000000120
crossref_primary_10_1089_vim_2008_0046
crossref_primary_10_1128_JVI_02111_12
crossref_primary_10_1002_hep_22684
crossref_primary_10_1002_hep_25765
crossref_primary_10_1089_vim_2016_0052
crossref_primary_10_1002_eji_200737888
crossref_primary_10_1089_aid_2012_0320
crossref_primary_10_1007_s11596_012_0093_8
crossref_primary_10_1111_j_1600_0838_2010_01288_x
crossref_primary_10_1111_imm_12006
crossref_primary_10_3390_vaccines12090992
crossref_primary_10_1016_j_jhep_2010_04_020
crossref_primary_10_1089_aid_2011_0353
crossref_primary_10_1111_sji_12018
crossref_primary_10_4049_jimmunol_1101649
crossref_primary_10_1016_j_cellimm_2013_02_004
crossref_primary_10_1128_IAI_01500_06
crossref_primary_10_3892_ijo_2014_2402
crossref_primary_10_1038_nri2189
crossref_primary_10_1016_j_vaccine_2008_03_026
crossref_primary_10_1371_journal_pone_0104627
crossref_primary_10_1016_j_ejphar_2013_01_064
crossref_primary_10_1038_nri3041
crossref_primary_10_1371_journal_pone_0040359
crossref_primary_10_1016_j_ijbiomac_2014_01_017
crossref_primary_10_3389_fcimb_2017_00247
crossref_primary_10_1007_s12250_014_3396_z
crossref_primary_10_1111_j_1751_7915_2011_00283_x
crossref_primary_10_4161_hv_28517
crossref_primary_10_1016_j_vaccine_2008_11_042
crossref_primary_10_1371_journal_pone_0151717
crossref_primary_10_1016_j_intimp_2021_107761
Cites_doi 10.4049/jimmunol.165.12.6833
10.4049/jimmunol.160.3.1212
10.1016/S0092-8674(00)80856-9
10.1016/S0952-7915(96)80034-3
10.4049/jimmunol.170.1.394
10.1038/87730
10.1146/annurev.immunol.18.1.927
10.4049/jimmunol.172.7.4123
10.1146/annurev.immunol.15.1.617
10.1084/jem.181.3.1047
10.1038/87720
10.4049/jimmunol.155.3.1151
10.1128/JVI.67.4.2376-2380.1993
10.4049/jimmunol.173.4.2211
10.1172/JCI200423395
10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#
10.1073/pnas.132254399
10.1146/annurev.iy.13.040195.000333
10.1084/jem.20011347
10.1038/nature01152
10.1084/jem.20030171
10.1016/S0002-9440(10)64980-2
10.4049/jimmunol.150.10.4659
10.1128/JVI.76.17.8609-8620.2002
10.1038/nri778
10.1089/hum.1995.6.11-1447
ClassificationCodes R5
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
2005 Baishideng Publishing Group Inc. All rights reserved. 2005
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
– notice: 2005 Baishideng Publishing Group Inc. All rights reserved. 2005
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
2B.
4A8
92I
93N
PSX
TCJ
5PM
ADTOC
UNPAY
DOI 10.3748/wjg.v11.i24.3772
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
EISSN 2219-2840
EndPage 3777
ExternalDocumentID 10.3748/wjg.v11.i24.3772
PMC4316033
wjg200524024
15968737
10_3748_wjg_v11_i24_3772
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Grant-in-Aid for Scientific Research
GroupedDBID ---
123
29R
2WC
36B
53G
5VR
8WL
92F
92I
AAKDD
AAYXX
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CITATION
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
HYE
OK1
P2P
RNS
RPM
TCJ
TGQ
TR2
WFFXF
XSB
2B.
93N
CGR
CUY
CVF
ECM
EIF
FA0
M~E
NPM
7X8
4A8
PSX
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c353t-a7cff9a18d6fb1c49619a5c4353b3d17e795e9cd4d5e35947290781b38b9b8383
IEDL.DBID UNPAY
ISSN 1007-9327
2219-2840
IngestDate Tue Aug 19 23:49:19 EDT 2025
Tue Sep 30 16:53:46 EDT 2025
Thu May 29 04:01:26 EDT 2025
Fri Jul 11 05:42:02 EDT 2025
Wed Oct 16 00:47:23 EDT 2024
Thu Apr 24 23:12:54 EDT 2025
Wed Oct 01 02:36:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 24
Keywords Regulatory T cell (Treg)
Vaccine
Hepatitis B virus
DNA immunization
Cytotoxic T lymphocyte
Language English
License cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c353t-a7cff9a18d6fb1c49619a5c4353b3d17e795e9cd4d5e35947290781b38b9b8383
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Kazuhiro Kakimi, MD, PhD, Department of Immunotherapeutics (Medinet), Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. kakimi@m.u-tokyo.ac.jp
Author contributions: All authors contributed equally to the work.
Telephone: +81-3-3815-5411 Fax: +81-3-5684-3989
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.wjgnet.com/1007-9327/full/v11/i24/3772.htm
PMID 15968737
PQID 67956131
PQPubID 23479
PageCount 6
ParticipantIDs unpaywall_primary_10_3748_wjg_v11_i24_3772
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4316033
wanfang_journals_wjg200524024
proquest_miscellaneous_67956131
pubmed_primary_15968737
crossref_citationtrail_10_3748_wjg_v11_i24_3772
crossref_primary_10_3748_wjg_v11_i24_3772
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-06-28
PublicationDateYYYYMMDD 2005-06-28
PublicationDate_xml – month: 06
  year: 2005
  text: 2005-06-28
  day: 28
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World J Gastroenterol
PublicationTitle_FL WORLD JOURNAL OF GASTROENTEROLOGY
PublicationYear 2005
Publisher Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan
Baishideng Publishing Group Inc
Publisher_xml – name: Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan
– name: Baishideng Publishing Group Inc
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref27
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref13
  doi: 10.4049/jimmunol.165.12.6833
– ident: ref23
  doi: 10.4049/jimmunol.160.3.1212
– ident: ref24
  doi: 10.1016/S0092-8674(00)80856-9
– ident: ref2
  doi: 10.1016/S0952-7915(96)80034-3
– ident: ref19
  doi: 10.4049/jimmunol.170.1.394
– ident: ref11
  doi: 10.1038/87730
– ident: ref8
  doi: 10.1146/annurev.immunol.18.1.927
– ident: ref27
  doi: 10.4049/jimmunol.172.7.4123
– ident: ref7
  doi: 10.1146/annurev.immunol.15.1.617
– ident: ref4
  doi: 10.1084/jem.181.3.1047
– ident: ref12
  doi: 10.1038/87720
– ident: ref22
  doi: 10.4049/jimmunol.155.3.1151
– ident: ref5
  doi: 10.1128/JVI.67.4.2376-2380.1993
– ident: ref26
  doi: 10.4049/jimmunol.173.4.2211
– ident: ref25
  doi: 10.1172/JCI200423395
– ident: ref17
  doi: 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#
– ident: ref15
  doi: 10.1073/pnas.132254399
– ident: ref21
– ident: ref1
  doi: 10.1146/annurev.iy.13.040195.000333
– ident: ref14
  doi: 10.1084/jem.20011347
– ident: ref18
  doi: 10.1038/nature01152
– ident: ref16
  doi: 10.1084/jem.20030171
– ident: ref3
  doi: 10.1016/S0002-9440(10)64980-2
– ident: ref6
  doi: 10.4049/jimmunol.150.10.4659
– ident: ref9
  doi: 10.1128/JVI.76.17.8609-8620.2002
– ident: ref10
  doi: 10.1038/nri778
– ident: ref20
  doi: 10.1089/hum.1995.6.11-1447
SSID ssj0023352
Score 1.9879061
Snippet Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and...
R5; AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome...
AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance...
SourceID unpaywall
pubmedcentral
wanfang
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 3772
SubjectTerms Animals
Brief Reports
CD4-Positive T-Lymphocytes - cytology
CD4-Positive T-Lymphocytes - metabolism
CD4-Positive T-Lymphocytes - virology
CD8-Positive T-Lymphocytes - cytology
CD8-Positive T-Lymphocytes - virology
DNA, Viral - immunology
Hepatitis B Vaccines - pharmacology
Hepatitis B virus - immunology
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - therapy
Immunization
Male
Mice
Mice, Inbred Strains
Receptors, Interleukin-2 - metabolism
Title Depletion of CD25 + CD4 + T cells (Tregs) enhances the HBV-specific CD8 + T cell response primed by DNA immunization
URI https://www.ncbi.nlm.nih.gov/pubmed/15968737
https://www.proquest.com/docview/67956131
https://d.wanfangdata.com.cn/periodical/wjg200524024
https://pubmed.ncbi.nlm.nih.gov/PMC4316033
https://www.wjgnet.com/1007-9327/full/v11/i24/3772.htm
UnpaywallVersion publishedVersion
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2219-2840
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023352
  issn: 1007-9327
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2219-2840
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023352
  issn: 1007-9327
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2219-2840
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023352
  issn: 1007-9327
  databaseCode: RPM
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaW7gEuPMQrwC4-cGBZ5VXbcXwsLasKiYpDC8spshOnWyhu1bSsll_PTJIWykqIPcceOfaM_Y1n5jMhryKRx7AHGp9LGfm8jDBIqKUfpRLGLTByg8XJH0bJcMLfn4vzA5Jsa2EwrfLy6xTc8nqbxhi-DxBDhngbHf6I43DW5SEDTAi-5fdb5DDBwFKHHE5GH3tf6tBm2wNflQNz9GH_jZr4JDKthCA8ADEBiAlQzP55dA1kXs-VvL1xS311qefzus7HldpN_ziSzu6Rz9ufaTJRvgWbtQnyn3_xPN78b--Tuy1Kpb1GrR6QA-seEjewS6TqXji6KGl_0BWn_QE_HVO8_K_o6_HKTqsTat0FalJFAVrS4dtPPhZzYkISdEnb1nTVpOZausTnBQpqruhg1KOzulqlqQx9RCZn78b9od8-1-DnTLC1r2VelkrHaZGUJs65At9MixzwGDOsiKWVSliVF7wQlgnFAdYj05BhqVEmBU_5Mem4hbNPCdVKiEIYnZSM8SLKFYDALpcps0rhLbZHwu2iZXnLZY5Paswz8GlwmTOYVfD_4wzmL8P588jJrsey4fH4R9uXWz3IwNhwWrSzi02VJRLrgFnskSeNVvyWJVSSSiY9Ivf0ZdcAabz3v7jZRU3njWQEEWMeebPTrP8Y4lGrelm751TYpqbR4gC7nt1E2HNypyakjRIwlheks15t7BFArbU5rm-_jlvr-gUsECNM
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaW7gEuPMRjAyz4wIFllVdtx_GxtKwqJCoOLSynyE6cbqG4VdOyWn49M0laKCsh9hx75Ngz9jeemc-EvIpEHsMeaHwuZeTzMsIgoZZ-lEoYt8DIDRYnfxglwwl_fy7OD0iyrYXBtMrLr1Nwy-ttGmP4PkAMGeJtdPgjjsNZl4cMMCH4lt9vkcMEA0sdcjgZfex9qUObbQ98VQ7M0Yf9N2rik8i0EoLwAMQEICZAMfvn0TWQeT1X8vbGLfXVpZ7P6zofV2o3_eNIOrtHPm9_pslE-RZs1ibIf_7F83jzv71P7rYolfYatXpADqx7SNzALpGqe-HooqT9QVec9gf8dEzx8r-ir8crO61OqHUXqEkVBWhJh28_-VjMiQlJ0CVtW9NVk5pr6RKfFyiouaKDUY_O6mqVpjL0EZmcvRv3h377XIOfM8HWvpZ5WSodp0VSmjjnCnwzLXLAY8ywIpZWKmFVXvBCWCYUB1iPTEOGpUaZFDzlx6TjFs4eEaqVEIUwOikZ40WUKwCBXS5TZpXCW2yPhNtFy_KWyxyf1Jhn4NPgMmcwq-D_xxnMX4bz55GTXY9lw-Pxj7Yvt3qQgbHhtGhnF5sqSyTWAbPYI08arfgtS6gklUx6RO7py64B0njvf3Gzi5rOG8kIIsY88manWf8xxONW9bJ2z6mwTU2jxQF2Pb2JsGfkTk1IGyVgLM9JZ73a2GOAWmvzorWrX12WIjw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Depletion+of+CD25%2BCD4%2BT+cells+%28Tregs%29+enhances+the+HBV-specific+CD8%2B+T+cell+response+primed+by+DNA+immunization&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Furuichi%2C+Yoshihiro&rft.au=Tokuyama%2C+Hirotake&rft.au=Ueha%2C+Satoshi&rft.au=Kurachi%2C+Makoto&rft.date=2005-06-28&rft.issn=1007-9327&rft.volume=11&rft.issue=24&rft.spage=3772&rft_id=info:doi/10.3748%2Fwjg.v11.i24.3772&rft.externalDBID=NO_FULL_TEXT
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fwjg%2Fwjg.jpg